Longeveron (LGVN) Research & Development (2020 - 2026)
Longeveron (LGVN) recorded quarterly Research & Development of $2.3 million in Q1 2026, down 14.74% quarter-over-quarter from $2.7 million in Q4 2025, and down 7.79% on a YoY basis from $2.5 million in Q1 2025.
Longeveron (LGVN) Research & Development (2020 - 2026) Analysis & Trends
Longeveron's Research & Development history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Research & Development fell 7.79% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $11.8 million (up 40.48% YoY), while the FY2025 annual figure was $12.0 million, up 47.98% from the prior year.
- Research & Development was $2.3 million for Q1 2026 at Longeveron, down from $2.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.9 million in Q3 2025 to a low of $1.3 million in Q1 2022.
- Historically, Research & Development has averaged $2.4 million across 5 years, with a median of $2.3 million in 2023.
- Biggest YoY gain for Research & Development was 115.17% in 2023; the steepest drop was 37.74% in 2023.
- A 5-year view of Research & Development shows it stood at $3.3 million in 2022, then slumped by 33.93% to $2.2 million in 2023, then declined by 7.75% to $2.0 million in 2024, then soared by 36.75% to $2.7 million in 2025, then fell by 14.74% to $2.3 million in 2026.
- The last three Research & Development figures came in at $2.3 million (Q1 2026), $2.7 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 1.72 Mn |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | 1.73 Mn |
| Sep 30, 2021 | 2.05 Mn |
| Jun 30, 2021 | 1.96 Mn |